CPT code 83884 represents a laboratory chemistry assay for neurofilament light chain (NfL), a blood- or CSF-based biomarker that can indicate neuronal injury across a range of neurological disorders. Nationally, NfL testing has clinical significance for neurology, neurodegenerative disease management, and research into inflammatory and traumatic brain conditions. Rising clinical interest in NfL testing has driven payer attention to coverage policies and reimbursement approaches.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role, common billing considerations, and the payer landscape. The publication outlines what types of services and sites typically use this code, common modifiers and service line notes (where available), and how NfL testing fits into broader laboratory and neurology practice patterns.

This summary provides practical context for clinicians, laboratory billing staff, and policy analysts: understanding the clinical indications for NfL testing, typical places of service, and the payer groups commonly involved. Data not available in the input for specific taxonomies, ICD-10 pairings, and related codes is noted elsewhere in the full publication.